Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Roche’s vision of developing an oral diabetic retinopathy treatment has taken a hit, with the drugmaker stopping development of vicasinabin after completing phase 2. The CB2 agonist was discarded as part of a cull that also saw Roche pull back from its CEAxCD3 bispecific candidate cibisatamab.